Anthem Biosciences IPO subscribed 67.42 times on the last day, while A retail quota was subscribed 5.98 times, QIB subscribed 192.80 times, and NII quota subscribed 44.70 times, respectively.
Details About Anthem Biosciences IPO
Anthem Biosciences got approval from SEBI for an IPO of ₹3,395 crores. This IPO comprises entirely an offer for sale up to 5,95,61,404 equity shares with a face value of ₹2 each.
Moreover, the company has set up a price band between ₹540 to ₹570 per share. In this IPO, a total of 26 shares were available in one lot size for the minimum Retail category, and 338 shares in 13 lot sizes for the maximum retail category. The S-HNI minimum category consists of 364 shares in a lot size of 14, and the B-HNI category has 1,768 shares in a 68 lot size.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,820 and maximum investment of ₹1,92,660.
- Small HNI (S-HNI): Minimum investment of ₹2,07,480.
- B-HNI Minimum (B-HNI): Minimum investment of ₹10,07,760.
Subscription Duration of the Anthem Biosciences IPO
The opening date for the Anthem Biosciences IPO subscription was July 14, 2025, whereas the closing date of the Anthem Biosciences IPO was July 16, 2025. The allotment of Anthem Biosciences Services, July 17, 2025, and the listing date schedule for July 21, 2025.
About Anthem Biosciences IPO
Incorporated in 2006, Anthem Biosciences Limited is a prominent innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with comprehensive operations spanning drug discovery, development, and manufacturing. It is one of the few companies in India with integrated capabilities in New Chemical Entities (NCE) and New Biological Entities (NBE) throughout drug discovery, development, and commercial manufacturing. The company serves various customers that including emerging biotech companies and large pharmaceutical companies across the world. The company has supplied to over 150 customers, from small biotech to large pharmaceutical companies, as of March 31, 2024. Currently, the company has a team of 600 employees. The company is involved in the manufacturing of specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
Financial Background of Anthem Biosciences IPO
The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crores in 2024. The company reported a profit of ₹451.26 crores in 2025 against a profit of ₹367.31 crores in 2024.
